uMed helps address critical evidence gaps in cardiometabolic disease research

  • uMed launches pioneering AccessCMD patient cohort facilitating access to custom data and insights to help accelerate cardiometabolic disease research
  • Cardiometabolic disease is now the leading cause of mortality globally and is placing a huge financial burden on healthcare systems and the economy
  • uMed have already recruited over 500 patients into the cohort, achieving over 15% consent rate from the first patient engagements sent, with significant potential for expansion across UK and US healthcare networks 

uMed has announced the successful enrollment of the first 500 UK participants into their groundbreaking AccessCMD cohort of patients with cardiometabolic disease.

AccessCMD will provide researchers with unique tools to access custom data and insights based on specific research criteria, to accelerate research and understanding across this group of conditions.

Cardiometabolic Disease encompasses a range of conditions including type 2 diabetes, stroke, hypertension, and congestive heart failure. It is now the number one cause of mortality across the globe, accounting for 31% of global deaths. [1] 

In the UK the NHS spends around £10 billion a year on type 2 diabetes, approximately 10% of its entire budget,[2] and it is estimated that £7.4 billion is being spent on healthcare related to CVD, with an annual cost to the wider economy of £15.8 billion.[3]

With the prevalence of cardiometabolic diseases on a sharp incline globally, research into this group of diseases is on the rise. 

Following the success of initial engagements sent to patients, which resulted in a 15% consent rate, uMed is now rolling out further engagements via their extensive UK healthcare provider network. 

uMed’s unique approach to patient identification, outreach, and consent, combined with fully decentralised data collection, mitigates biases that often arise in research due to factors such as patient location, socioeconomic circumstances, race, gender, and age.

‘The conversion rate we achieved from our first engagements is compelling; if we extrapolate this rate to the eligible patient population covered by our healthcare provider network in the UK, we’ll be able to offer thousands of patients the opportunity to participate in research and very quickly build a unique and rich source of information in Cardiometabolic Disease” commented Anil S. Jina, MD, Chief Medical Officer & President North America, at uMed.

Unlike traditional registries that are static and do not easily allow for the generation of custom data, AccessCMD enables re-engagement with patients that have already consented to participate in additional studies. This allows for the rapid collection of custom data that holds the answer to specific research questions, in the form of electronic health records, clinical outcomes, patient-reported outcomes and biosamples. 

Dr Mark Toshner, Consultant Respiratory Physician at the University of Cambridge, and AccesssPD Principal Investigator, commented “The potential that AccessCMD holds for research is extensive. The prevalence of these diseases has grown at a substantial rate over the past 20 years and the consequence is a huge burden on the populations’ health and our healthcare systems,  so there is much research to be done to understand the mechanisms contributing to these poor health outcomes.

“Conducting research at a large-scale with patient groups that represent the entire population is essential for developing a true understanding of the disease and underlying burden or unmet needs. The challenge for researchers is finding enough patients that meet the very specific criteria to conduct robust studies.’

“AccessCMD provides researchers with access to custom data to answer their key research questions, as and when required, and even enables the running of standalone studies within the infrastructure of the existing cohort. This will significantly expedite the development of understandings and treatments to reduce the burden of these diseases.”

The launch of AccessCMD follows the success of uMed’s inaugural AccessPD cohort study, which has so far recruited over 500 patients diagnosed with Parkinson’s Disease in the UK, 

Additionally, the company has recently begun the roll-out of engagements to patients with Interstitial Lung Disease, with nearly 100 patients in the UK now consented into their AccessILD cohort.

The swift succession of AccessCMD underscores the popularity of uMed’s Cohort Platform Studies amongst both patients and healthcare providers, highlighting the value for researchers within cardiometabolic disease and many more disease areas. 

Plans are underway to launch AccessPD, AccessILD and AccessCMD in the USA in 2024.

 

 

[1] https://www.roche.com/solutions/focus-areas/cardiometabolic

[2] https://www.england.nhs.uk/2022/03/nhs-prevention-programme-cuts-chances-of-type-2-diabetes-for-thousands/

[3] https://www.gov.uk/government/publications/health-matters-preventing-cardiovascular-disease/health-matters-preventing-cardiovascular-disease#:~:text=Yearly%20healthcare%20costs%20in%20England,economy%20of%20%C2%A315.8%20billion.

Manuscript: AccessPD as a next generation registry to accelerate Parkinson’s disease research

We are excited to share our first manuscript from AccessPD, co-authored by Dr. Yun Hsuan Chang from uMed and Professor Alastair Noyce from Queen Mary University of London, now published in the Nature Journal – NPJ Parkinson’s Disease.

Access the full publication here.

AccessPD represents a ‘next generation’ registry in Parkinson’s Disease, leveraging uMed’s ACCESS Research Platform to merge clinical outcomes from electronic health records with patient-reported outcomes directly from those within the AccessPD cohort.

The authors have adeptly presented the most common diagnoses before and after a Parkinson’s Disease diagnosis, the most commonly prescribed medications among the cohort, and identified participants who could potentially benefit from device-aided therapies using consensus criteria.

uMed helps researchers move closer to understanding Parkinson’s risk factors

uMed helps Queen Mary University of London and University College London move closer to understanding Parkinson’s risk factors as first-of-its-kind study exceeds 10,000 participant milestone

  • PREDICT-PD a joint study between Queen Mary University of London and University College London (UCL), and funded by Parkinson’s UK, has met its goal of enrolling more than 10,000 participants.
  • The research project, which identifies and engages people aged between 60 and 80 years old who did not have Parkinson’s, aims to identify those at high risk of the disease before symptoms appear.
  • uMed enrolled over 7,000 eligible participants through its network of 500 primary care group providers in the UK, and increased monthly enrollment by 275%.
  • Over one in 10 patients invited by uMed consented to participate, compared to the industry average patient consent rate of 3% for clinical research.
  • uMed’s involvement also led to the enrollment of a larger population of patients from ethnic minority groups, increasing diversity from ~3% to ~10% of the study’s total cohort.

LONDON, 14 February 2024: PREDICT-PD a groundbreaking research project, which aims to identify people at higher risk of Parkinson’s disease or before the symptoms appear, has exceeded its milestone of 10,000 participants.

uMed, the health and research technology company that has supported PREDICT-PD since March 2020, played a crucial role in expanding the study’s participant base through its network of over 500 primary care provider groups representing five million patients in the UK. It achieved this by linking aggregated health record data to pre-screen eligible participants, meaning it was able to rapidly engage 36,269 patients via text message on behalf of the patients’ healthcare providers, without imposing any additional workload.

By making the study accessible to a wider population and engaging only suitable patients, uMed has recruited over 7,000 participants to PREDICT-PD, increasing monthly enrollment by a staggering 275%. Over one in 10 patients invited by uMed on behalf of their recognised healthcare provider consented to participate in the study, which is a significant achievement given that only 2% of the population in England participates in clinical trials each year, underscoring uMed’s ability to engage a larger portion of the UK population in vital clinical research.

Professor Alastair Noyce, Consultant Neurologist and Researcher at Queen Mary University of London’s Wolfson Institute of Population Health, comments: “Our study was one of the first to focus on the earliest phases of Parkinson’s, offering critical insights into this stage of the disease, and recruitment has progressed at a pace we never expected. We are another step closer to understanding who in the general population might be more likely to be diagnosed with Parkinson’s and expedite the discovery of improved treatments and, ultimately, a cure for this debilitating condition.

“The success of the PREDICT-PD study demonstrates the impact of leveraging technology and the use of health record data to accelerate research. uMed’s ability to rapidly identify large populations of eligible participants using EHR, combined with automated communication sent on behalf of the patient’s healthcare provider, has meant we’ve seen a significant increase and speed in enrollment each month since working with them.”

Dr Katherine Fletcher, Research Communications Lead at Parkinson’s UK, comments: “This is one of several ground-breaking studies Parkinson’s UK is proud to be funding and we are delighted that there’s been such a positive take-up in research participation for PREDICT-PD.”

“We know Parkinson’s doesn’t discriminate. It is vital that research is representative of the whole Parkinson’s community, something that currently is not the case. Having a wider pool of the UK population involved in clinical trials means we can ultimately learn more about the progression of Parkinson’s, speed up diagnosis and access to new and better treatments for all.”

Notably, uMed’s involvement has led to the enrollment of a large population of patients from ethnic minorities, increasing diversity of the study’s total cohort from 3% to 10%. Its technology enabled participating healthcare providers to move away from standardised patient outreach to individually tailor communications. By using Electronic Health Records (EHR) to segment cohorts into different subgroups, eligible patients could be targeted with bespoke messages or visuals, increasing participation of underrepresented groups.

Ethnic diversity is a vital issue in Parkinson’s research however people from minority backgrounds continue to be underrepresented. The large majority of UK participants are affluent, well-educated and white. This is currently reflected in research not only in the UK but across Europe and North America It means understanding the genetic basis, environmental risk factors, clinical manifestations and response to treatment is heavily biased, as described in Ethnic Variation in the Manifestation of Parkinson’s Disease, a paper co-authored by Professor Alastair Noyce.

Dr Matt Wilson, uMed’s founder and CEO, adds: “Despite a step change in awareness on the need for diverse participants, clinical trials in western health systems fail to reflect real world diversity. Particularly, there is limited evidence on the risk factors of Parkinson’s in Black, Asian and Hispanic populations but PREDICT-PD has clearly increased ethnic diversity and therefore the generalisability of its findings for the general UK population.

“The study team at Queen Mary University of London achieved this by targeting eligible participants, who identified as being from an ethnic minority, with images of ethnically diverse patients in study communications. Tailoring communications in this way resulted in a significant increase in the proportion of participants coming from a minority background.”

In addition to uMed’s collaboration with Professor Alastair Noyce on the PREDICT-PD study, he is also principal investigator on uMed’s ongoing observational study AccessPD, a next-generation patient registry supporting the development of better treatments for patients with Parkinson’s.

For more information about uMed and how the company is supporting Parkinson’s Disease research, please get in touch.

Redefining Patient Engagement Through Consumer Insights

In this article uMed’s CEO Matt Wilson discusses the untapped potential of harnessing data-led insights to drive personalized, meaningful consumer experiences within the healthcare sector. He examines how tailored communication and bespoke engagement throughout a patient’s healthcare journey has the potential to enhance health outcomes and reduce provider costs. And how it’s the key to opening up better engagement with clinical trials, new drugs and treatments, encouraging healthier behaviors and building trust with healthcare customers.

Read the full article here: Read Article

Why Technology is Key to Unlocking Clinical Trial Access in Underserved Communities

A great article from our CEO Matt Wilson featured in The Journal of mHealth on the use of technology to address the challenges of access to clinical trial participation in underserved communities.

The article emphasizes the need to support smaller, local healthcare providers that serve as a gateway to underrepresented, less wealthy communities, to build trust and address the disparity in clinical trial participation.

Using technology can alleviate the organizational burden of clinical trials on these smaller providers, and embed recruitment in routine practice.

Additionally, technology provides opportunity for tailored patient outreach and the inclusion of non-English speakers, ultimately democratizing research and promoting diversity.

Read the full article here.

uMed Partners with The Michael J. Fox Foundation

uMed Partners with The Michael J. Fox Foundation to Support Wide-scale Study Exploring Link Between Smell Loss and Parkinson’s

  • uMed partners with The Michael J. Fox Foundation to run its smell test study in the UK as part of a global programme to explore the link between smell loss and Parkinson’s disease
  • uMed will enroll eligible patients from over 500 primary care group providers and facilitate the distribution of 15,000 scratch-and-sniff home tests
  • Its technology and network address challenges facing clinical trials, which include engaging large and inclusive patient cohorts as well as empowering over-stretched healthcare professionals to contribute to important research

LONDON, 20 September 2023: uMed, the health and research technology company, today announced The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has selected its service to support the global expansion of its wide-scale study exploring the link between loss of smell and brain disease.

The smell test study, which is part of MJFF’s landmark brain health initiative, the Parkinson’s Progression Markers Initiative (PPMI), will utilise uMed’s network of more than 500 primary care provider groups in the UK to engage eligible participants. uMed will facilitate the distribution of 15,000 University of Pennsylvania Smell Identification Tests (UPSIT), a scientifically validated scratch-and-sniff test of smell ability, to individuals aged 60 and older in the UK without Parkinson’s.

Current research into Parkinson’s indicates that 100% of major brain disorders are associated with smell loss and 96% of newly diagnosed Parkinson’s patients have lost some of this sense. In addition, the condition can precede diagnosis by years or even decades.

However, the challenge — as with many research studies — is in engaging large patient cohorts that represent a diverse population. While large academic centres and research sites are set up to support research, many struggle to enrol and retain large numbers of patients. Reuse of limited, local clinical populations can also affect the generalisability of findings to the wider population.

Across all research, 85% of clinical trials face delays and 30% never get off the ground due to a lack of volunteers. By leveraging technologies such as uMed, it’s possible to rapidly and efficiently reach more participants and enable the delivery of larger, more ambitious trials than ever before.

By partnering with uMed, The Michael J. Fox Foundation can access hundreds of primary care providers whose involvement in clinical studies is critical for the advancements in research. Without uMed, these non-traditional research sites often lack the financial and human capital or the technical tools required to regularly engage their patients while balancing care.

uMed will send an SMS invite to potential participants, aged over 60 and without a diagnosis of Parkinson’s, on behalf of the patient’s recognised care provider before taking them to a screening portal. The free and simple scratch-and-sniff tests will then be delivered to consenting participants who will upload their results online. Eligible volunteers will be contacted by a nurse and referred to a clinic site for additional follow-up. Volunteers who join PPMI at a site share critical information through clinical assessments, imaging scans and biological samples over at least five years.

“Advances toward better treatments and cures for Parkinson’s disease require partnership with a diverse, broad base of study participants,” says Maggie Kuhl, MJFF Vice President of Research Engagement. “More simple and efficient tools that can deliver participation opportunities will help us overcome barriers to engagement and connect with more potential volunteers. uMed’s network and service is a valuable tool in helping our PPMI study drive faster recruitment of representative populations, speeding breakthroughs for all.”

The study, which has started enrollment in the UK, has already seen increased engagement of potential volunteers wanting more information and consenting to receive smell tests at home. To date, a third of patients who have been sent an SMS invitation to the study are clicking through to the study website to find out more information. In addition, 11% have consented to receive a smell test kit at home.

Dr Matt Wilson, uMed’s founder and CEO, comments: “We are proud to play our part in accelerating significant advancements in Parkinson’s research. Our technology will help The Michael J. Fox Foundation to reach its goals of driving more than 100,000 UPSIT completions globally. Engaging with a patient cohort of this size is critical if we are to enhance our understanding of this progressive disease and develop advanced therapies to improve patient outcomes.”

Wilson adds, “That being said, we know how hard it is to get impactful research off the ground. Our technical infrastructure and consumer-based marketing techniques enable researchers to develop, manage and engage large-scale patient cohorts in research programs. What’s more, we are democratising access to research for non-traditional research sites and their patients who might otherwise lack the technical infrastructure and staff capacity required to engage tens of thousands of patients across multiple studies. The result is that many patients contacted by uMed have never been invited to participate in research before. In a separate Parkinson’s study supported by uMed, more than 80% of patients reported they had never been asked to participate in research before.”

The partnership between uMed and The Michael J. Fox Foundation follows uMed’s experience in successfully delivering other Parkinson’s studies including the Predict-PD study run by Queen Mary University of London (also a PPMI clinical site). uMed increased monthly patient enrolment by 275%, as well as successfully recruiting a large population of patients from ethnic minorities. It is also running an ongoing observational study AccessPD, a next-generation patient registry which is supporting the development of better treatments for patients with Parkinson’s.

– ENDS –

uMed raises £9.8m to boost participation in clinical trials, expanding to N.America

 

  • Late-stage industry clinical research in the UK fell by 41% between 2017 and 2021, which is putting future patient care at risk
  • The healthtech’s latest round of funding will directly combat this problem by accelerating research and care support for targeted patient groups through its landmark cohort programmes
  • The successful raise will also be used to expand uMed’s presence in North America, increasing the company’s global patient access to over 10 million people by the end of 2023

 

LONDON, 5th July 2023: uMed, the health and research technology company, has raised £9.8 million in its latest venture capital funding round, which it will use to boost participation in clinical trials. The raise is backed by Delin Ventures, AlbionVC, Playfair Capital and Silicon Valley’s 11.2 Capital.

The UK is facing a collapse in industry clinical trials. Patient access to industry clinical trials has dropped by 44% between 2017/18 and 2021/22, and the number of trials initiated in the UK – including cancer trials – plummeted by 41% in a similar time frame. This is raising alarm about the future of clinical research in the UK and the resulting impact on patient care. uMed directly tackles this issue by enabling healthcare providers in the UK, US and Canada to more easily participate in clinical research and care improvement activity without additional cost or burden to staff. The uMed platform rapidly finds and engages suitable patients, and collects prospective data to answer key clinical questions, while also enabling GPs to generate additional revenue for their practice. This is in line with last month’s review by Lord O’Shaughnessy which urged the Government to provide financial incentives to GPs to help boost commercial clinical trials.

The latest funding round will extend the reach of uMed’s landmark cohort programme in Parkinson’s Disease, Access-PD, to several thousand patients globally by the end of the year. Access-PD, which already has over 350 participating patients in the UK via more than 130 GPs, is the first true population-scale research platform and closes the fundamental gap between the clinical data needs of researchers and their ability to access that data. This is achieved by creating consented cohorts that integrate near real-time Electronic Health Record (EHR) data with prospective data and biosamples captured from the patient at home. Additionally, uMed will be launching a Cardio-Metabolic Cohort and Lung Disease Cohort. It will initially focus on interstitial lung diseases like pulmonary fibrosis which is being developed with US research charity the Three Lakes Foundation.

uMed’s founder and CEO, Dr Matt Wilson comments: “We developed the uMed platform to help healthcare professionals more easily and efficiently run patient research and targeted care programmes at scale, improving outcomes for patients by mitigating care gaps and accelerating research. Our groundbreaking patient cohorts give researchers access to unique data and insights, accelerating development and access to new therapies, while dramatically reducing the cost of finding, engaging and collecting prospective data from patients.”

Dr Elango Vijakumar, National Research Lead at Modality Partnership, a provider of primary health care and community services across the UK, adds: “Clinical research is vital for innovation and to enhance the standard of patient care within the NHS. At the Modality Partnership, we are committed to actively supporting research. We’ve been working alongside uMed since 2019 to provide our patients with the opportunity to participate in multiple research programmes. Its management of patient identification and communication on our behalf allows us to be involved in cutting-edge research without compromising our focus on patient care. Without the platform to take on the admin and workload, there simply wouldn’t be the capacity to take part.”

The North America expansion builds on uMed’s UK successes – since its seed round in November 2020, uMed has signed up more than 450 UK GPs representing five million patients, and has successfully recruited over 6,000 patients to clinical studies. The entry into the US market will be spearheaded by a partnership deal with digital healthcare company Innovaccer, opening up access to over seven million patients across the country. This follows uMed’s inaugural Canadian partnership with clinician-led healthtech MCI Onehealth. These moves will be closely followed by a pipeline of deals that include direct health systems access and additional channel partners which will give uMed access to over 10 million patients by the end of 2023.

Since its 2020 seed round, uMed’s technology has enabled a number of successful nationwide studies to take place across the UK, including a prospective precision medicine clinical trial for patients with high hypertension and a nationwide study into identifying risk of Parkinson’s Disease.

Molly Gilmartin, Investor at AlbionVC, said: “At AlbionVC we are thrilled to continue partnering with Matt Wilson and his team to enable longitudinal research which has historically taken decades and cost millions of pounds. uMed’s technology is uniquely positioned to truly revolutionise how clinical research is conducted globally. The latest round of funding will continue to support the company’s US expansion and will further accelerate the next phase of growth on a path to global category leadership.”
Rosie Barnett, Principal at Delin Ventures, commented: “Delin Ventures is delighted to continue supporting uMed’s team in executing our shared vision, deploying digital health technology to revolutionise the future of trials and medical insight generation on a global scale – focusing now on the US. The traditional clinical research model is slow and expensive. uMed provides a unique platform to engage patients at scale in a highly targeted and cost-effective manner.”

Read more on Sky News.

Patient Story: Kevin Quinn

In 2022, Kevin Quinn from Liverpool joined a uMed supported study of patients with chronic respiratory conditions. The study evaluated the effectiveness of a respiratory monitor that measures CO2 levels in tidal breathing of participants. The aim of the research was to help advance the development of point-of-care diagnostic technologies that monitor and manage cardiorespiratory conditions, which have the potential to transform the way we diagnose and treat patients.

We caught up with Kevin upon completion of the study to find out more about his reasons for taking part and to hear about his experiences of participating in this research with uMed. Find out what he had to say…


Why did you choose to join this study?

I had been suffering from a lung condition for some time, so when I received the message about this study from my GP, I was keen to get involved and support any research that had the potential to improve knowledge and understanding of respiratory conditions, and that might bring some relief to others in the future.


How would you describe your experience of taking part in this study?

The whole process went smoothly, uMed handled everything so I was able to participate entirely from home and didn’t have to travel!

I was called by uMed’s Lead Research Nurse, Hannah, who was extremely helpful and professional in talking me through the study and ensuring I was happy to proceed.

I then received a study questionnaire and the respiratory device via post, and the uMed team walked me through how to use the device and how to record my daily symptoms. They also arranged for return of the devices once the study had finished.

I only have praise for the uMed team, their support was 10 out of 10! In particular Hannah was extremely helpful, friendly and professional, and was available to answer any questions I had about the study. This made me, and my wife, feel completely at ease with taking part.


What message do you have for others about participating in research?

Participating in research is so important. As individuals we own all this important information about our health that if shared could have a great impact on the lives of others in the future. How else can new treatments be developed if we don’t share this information?


Want to find out more about this study?

Find out how uMed supported the successful enrolment of 740 patients in to this study, whilst also handling device distribution, device training, and the collection and aggregation of key data to demonstrate efficacy of the device. Read the full case study here.

MCI Onehealth Partners with uMed to Accelerate Clinical Research

Partnership introduces unique patient recruitment and engagement platform to Canada

TORONTO, March 09, 2023 (GLOBE NEWSWIRE) — MCI Onehealth Technologies Inc. (“MCI”) (TSX: DRDR), a clinician-led healthcare technology company focused on increasing access to and quality of healthcare, and uMed, the UK-based provider of a leading automated patient-recruitment platform, are pleased to announce a partnership that will increase patient access to international research studies and accelerate enrollment and improve retention in clinical trials. MCI is uMed’s first Canadian partner.

“MCI’s collaboration with uMed will open a new subset of research that emphasizes real-world evidence and patient-reported information. MCI firmly believes that patient-facing technology is a core component for increasing access to healthcare and for making care more personalized,” said Dr. Alexander Dobranowski, founder and CEO of MCI. “MCI is already uniquely positioned in that we use technology to screen clinical data efficiently and compliantly to flag patients as potential participants for research trials. Once potential participants are flagged from among our more than three million patient records, uMed provides a highly efficient and incredibly fast method for contacting, enrolling, and ongoingly engaging these MCI patients, for any current clinical trial and for future relevant trials. This collaboration creates another innovative avenue by which MCI’s clinical insights as a service program can help optimize patient care, provide access to meaningful clinical trial opportunities and bring value to life sciences stakeholders and health systems.”

uMed connects healthcare professionals and their patients with ground-breaking research opportunities. Their digital patient recruitment platform enables healthcare professionals to participate in more research with minimal additional workload, providing their patients with better access to studies that are highly relevant to their specific condition.

uMed’s ability to capture patient-reported outcomes and real-world evidence is in demand for advancing clinical insights and fosters patient-empowerment. Their platform and approach are fully compliant with all relevant requirements for consent, privacy, data security and research ethics for clinical research, additionally allowing for opportunities to more easily and compliantly re-engage patients for follow-up or related trials.

“We’re thrilled to partner with innovators like MCI for our entry into Canada. Our two companies are aligned in the vision of how access to research can help optimize health for specific patients and more broadly across populations. Faster and more customizable cohorts in interventional and non-interventional clinical trials lead to better care options sooner, and more cost efficiently,” said Dr. Matt Wilson, CEO of uMed. “In MCI we see a partner that not only shares uMed’s driven commitment to supporting effective, efficient clinical research, but also a company with the existing clinical data lake to immediately utilize the uMed platform for significant outcomes.”

In keeping with its objective to be a preeminent health technology leader, MCI nurtures international opportunities to leverage its vast pool of high-quality structured clinical information. MCI’s audience for clinical insights continues to grow in Canada and the US and will further benefit from collaboration with international leader uMed.

About MCI:
MCI is a healthcare technology company focused on empowering patients and doctors with advanced technologies to increase access, improve quality, and reduce healthcare costs. As part of the healthcare community for over 30 years, MCI operates one of Canada’s leading primary care networks with approximately 280 physicians and specialists, serves more than one million patients annually and had nearly 300,000 telehealth visits last year, including online visits via mciconnect.ca. MCI additionally offers an expanding suite of occupational health service offerings that support a growing list of nearly 600 corporate customers. MCI provides data insights as a service in six categories: rare disease; complex major medical/chronic; patient cohort building; clinical trial recruitment; synthetic health data and bespoke insights. Led by a proven management team of doctors and experienced executives, MCI remains focused on executing a strategy centered around acquiring technology and health services that complement the company’s current roadmap. For more information, visit mcionehealth.com

About uMed
uMed is a healthcare technology company dedicated to accelerating clinical trials by making participation in research more accessible for healthcare professionals and their patients. The uMed platform takes on the workload of recruiting patients for clinical studies by automating the process of identification, screening, and engagement, all on behalf of the patient’s recognized provider. The technology seamlessly links clinical data from consented patients to ePROs, device data, and biosamples to rapidly create study-specific datasets and registries. This enables healthcare professionals to participate in more revenue-generating research with minimal additional workload, and provides patients with better access to life changing studies. uMed is embedded across a global network of providers that represent over 10 million lives across the UK, US, Canada and Australia. For more information, visit https://www.umed.io/


For media enquiries please contact:

Nolan Reeds | MCI Onehealth | nolan@mcionehealth.com
Lucy White | uMed | lucy.white@umed.io

First of its kind patient cohort program announced at IPF-Summit

NEW YORK, August 29, 2022 — A first-of-its-kind patient cohort platform will soon be available to UK and US researchers struggling to recruit patients with interstitial lung disease (ILD), such as pulmonary fibrosis and progressing fibrosis resulting from COVID-19. UK-based company uMed announced the launch of the Access-ILD/PF Cohort at the sixth annual Idiopathic Pulmonary Fibrosis (IPF) Summit in Boston.

uMed has built a technology that can rapidly identify, directly engage and quickly recruit patient populations at a significantly faster rate for participation in both clinical and real-world studies.

“Research in the life sciences industry is often a long process, especially in the rare disease space, where it can take several years to complete,” said Matt Wilson, MD, founder and president of uMed. “Our pioneering platform is designed to solve the challenges that researchers and patients are facing — delays in new therapies.”

According to Dr. Wilson, the uMed platform connects electronic medical records (EMR) with hospitalization data, patient-reported outcomes, medical device data and even DNA sampling to identify cohorts of patients eligible to participate in various studies. These include clinical trials and prospective observational research. It is the only platform capable of synergistically linking these multiple health data points.

“Right now, there are more than 200 clinical trials in various stages for ILD and PF/IPF,” noted Dr. Wilson. “With such a deep pipeline and more trials on the horizon, there is a significant demand for patient participation. This platform builds on the work we successfully initiated in the UK, with a goal of creating a global cohort to support multiple studies.”

“The tremendous progress we are seeing in how pulmonary fibrosis develops has resulted in several effective therapies,” added Fernando Martinez, MD, executive vice chair of medicine at Weill Cornell Medical College and New York-Presbyterian Hospital/Weill Cornell Medical Center. “While there are many active studies to come, a major limitation is identifying patients who would consider participating in a clinical trial. uMed offers a very promising approach that could revolutionize the rapid completion of key clinical studies for patients.”

Another unique aspect of the uMed platform is the inherent trust that the company has built with physicians, enabling them to strike a strategic partnership, engage with their patients and seek consent. Currently, the uMed network covers more than five million patients across the US and UK and will soon expand into Australia. The platform is HIPAA- and GDPR-compliant.

For more information about uMed’s unique platform or to see a demonstration, contact James Dunstan, VP Commercial at james.dunstan@umed.io, +44 (0) 7488 812 678.